MBX Biosciences, Inc. (MBX)
53.49
+0.39
(+0.73%)
USD |
NASDAQ |
Nov 18, 16:00
54.20
+0.71
(+1.33%)
After-Hours: 20:00
MBX Biosciences Total Assets (Quarterly) : 500.62M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 500.62M |
| June 30, 2026 | 435.91M |
| March 31, 2026 | 452.70M |
| December 31, 2025 | 385.14M |
| September 30, 2025 | 400.08M |
| June 30, 2025 | 231.52M |
| Date | Value |
|---|---|
| March 31, 2025 | 245.93M |
| December 31, 2024 | 268.54M |
| September 30, 2024 | 282.40M |
| June 30, 2024 | 62.88M |
| March 31, 2024 | 75.32M |
| December 31, 2023 | 84.18M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 2.237B |
| Xeris Biopharma Holdings, Inc. | 423.22M |
| ANI Pharmaceuticals, Inc. | 1.568B |
| Corcept Therapeutics, Inc. | 1.034B |
| Veru, Inc. | 37.03M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 27.67M |
| Shareholders Equity (Quarterly) | 472.95M |
| Debt to Equity Ratio | 0.007 |
| Current Ratio | 19.58 |
| Net Debt Paydown Yield | -0.02% |